{"id":"luvox-cr","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"8-12","effect":"Asthenia/fatigue"},{"rate":"8-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Anorexia"},{"rate":"5-15","effect":"Sexual dysfunction"}]},"_chembl":{"chemblId":"CHEMBL1628102","moleculeType":"Small molecule","molecularWeight":"468.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluvoxamine, the active ingredient in Luvox CR, selectively inhibits the reuptake of serotonin at the serotonin transporter (SERT), leading to increased serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is thought to improve mood regulation and reduce anxiety and obsessive-compulsive symptoms. The extended-release formulation provides sustained drug levels throughout the day.","oneSentence":"Luvox CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:35.289Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obsessive-compulsive disorder (OCD)"},{"name":"Social anxiety disorder"}]},"trialDetails":[{"nctId":"NCT04510194","phase":"PHASE3","title":"COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2021-01-01","conditions":"Covid19, SARS-CoV Infection","enrollment":1323},{"nctId":"NCT04727424","phase":"PHASE3","title":"Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms","status":"RECRUITING","sponsor":"Cardresearch","startDate":"2021-01-19","conditions":"Covid19, SARS-Associated Coronavirus","enrollment":7819},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT04668950","phase":"PHASE3","title":"Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-12-22","conditions":"Covid19, Coronavirus","enrollment":670},{"nctId":"NCT02022709","phase":"PHASE4","title":"Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2014-01","conditions":"Obsessive-Compulsive Disorder, Anxiety Disorders, Mental Disorders","enrollment":78},{"nctId":"NCT05216614","phase":"PHASE2","title":"Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2021-12-14","conditions":"COVID-19, Olfactory Disorder, Parosmia","enrollment":""},{"nctId":"NCT04342663","phase":"PHASE2","title":"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-04-10","conditions":"COVID 19, Coronavirus","enrollment":152},{"nctId":"NCT01933919","phase":"PHASE3","title":"A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-14","conditions":"Obsessive Compulsive Disorder","enrollment":38},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT01908296","phase":"PHASE1","title":"Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-07","conditions":"Healthy, Pharmacokinetics of Quetiapine","enrollment":24},{"nctId":"NCT02442713","phase":"NA","title":"The Effect of Fluvoxamine on Polysonogram in Depressed Patients With Insomnia","status":"UNKNOWN","sponsor":"Guang Dong Provincial Mental Health Institute","startDate":"2014-11","conditions":"Depression","enrollment":30},{"nctId":"NCT01460212","phase":"PHASE4","title":"Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2011-12","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT01831440","phase":"NA","title":"Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2011-01","conditions":"Depressive Disorder","enrollment":200},{"nctId":"NCT00645580","phase":"NA","title":"Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function","status":"UNKNOWN","sponsor":"Sha'ar Menashe Mental Health Center","startDate":"2008-04","conditions":"Schizophrenia","enrollment":15},{"nctId":"NCT00743834","phase":"PHASE4","title":"Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)","status":"UNKNOWN","sponsor":"Rogers Center for Research & Training, Inc.","startDate":"2008-09","conditions":"Obsessive Compulsive Disorder","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":14,"reaction":"INSOMNIA"},{"count":13,"reaction":"WEIGHT INCREASED"},{"count":12,"reaction":"ANXIETY"},{"count":12,"reaction":"DRUG INEFFECTIVE"},{"count":12,"reaction":"SOMNOLENCE"},{"count":10,"reaction":"FATIGUE"},{"count":9,"reaction":"DEPRESSION"},{"count":8,"reaction":"ABDOMINAL PAIN UPPER"},{"count":8,"reaction":"NAUSEA"},{"count":7,"reaction":"DYSPNOEA"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Luvox CR","genericName":"Luvox CR","companyName":"Rogers Center for Research & Training, Inc.","companyId":"rogers-center-for-research-training-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Luvox CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron. Used for Obsessive-compulsive disorder (OCD), Social anxiety disorder, Depression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}